MIFH
MTNB icon

Migdal Insurance & Financial Holdings’s Matinas BioPharma MTNB Stock Holding History

Migdal Insurance & Financial Holdings’s Portfolio MTNB Stock Details MTNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-117
Closed -$6K – 660
2021
Q4 		$6K Sell
117
-70
-37% -$3.74K ﹤0.01% 639
2021
Q3 		$12K Buy
+187
New +$8.07K ﹤0.01% 584

Other funds holding MTNB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
CCM
Courage Capital Management Nashville, Tennessee $70.6M AUM 13.29% 1-Year Est. Return
JEST
JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return

Migdal Insurance & Financial Holdings's MTNB Position: Q1 2022 in Review

Migdal Insurance & Financial Holdings sold out of Matinas BioPharma (MTNB) in Q1 2022, closing a stake of 117 shares — an estimated $6K sold.

Migdal Insurance & Financial Holdings first reported a position in MTNB in Q3 2021 and held it in 2 quarters. The position peaked at $12K in Q3 2021. 56 funds tracked by Wall St. Rank hold MTNB as of Q1 2022.

  • Migdal Insurance & Financial Holdings reported no remaining Matinas BioPharma position as of Q1 2022 after selling out during the quarter.
  • Migdal Insurance & Financial Holdings sold 117 Matinas BioPharma shares in Q1 2022, an estimated $6K.
  • Migdal Insurance & Financial Holdings first reported a position in Matinas BioPharma in Q3 2021 and held it in 2 quarters.
  • Migdal Insurance & Financial Holdings's Matinas BioPharma position peaked at $12K in Q3 2021.
  • 56 funds tracked by Wall St. Rank held Matinas BioPharma as of Q1 2022.

Based on Migdal Insurance & Financial Holdings's 13F filing for Q1 2022, filed 2 May 2022.